Traws Pharma Future Growth
Future criteria checks 0/6
Traws Pharma is forecast to grow revenue at 1% per annum. EPS is expected to grow by 85.6% per annum.
Key information
n/a
Earnings growth rate
85.6%
EPS growth rate
| Pharmaceuticals earnings growth | 21.3% |
| Revenue growth rate | 1.0% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 27 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 0 | N/A | N/A | N/A | 1 |
| 12/31/2024 | 0 | N/A | N/A | N/A | 1 |
| 9/30/2024 | 0 | -141 | -30 | -30 | N/A |
| 6/30/2024 | 0 | -137 | -23 | -23 | N/A |
| 3/31/2024 | 0 | -18 | -18 | -18 | N/A |
| 12/31/2023 | 0 | -19 | -18 | -18 | N/A |
| 9/30/2023 | 0 | -20 | -17 | -17 | N/A |
| 6/30/2023 | 0 | -21 | -17 | -17 | N/A |
| 3/31/2023 | 0 | -21 | -17 | -17 | N/A |
| 12/31/2022 | 0 | -19 | -16 | -16 | N/A |
| 9/30/2022 | 0 | -17 | -17 | -17 | N/A |
| 6/30/2022 | 0 | -15 | -17 | -17 | N/A |
| 3/31/2022 | 0 | -16 | -17 | -17 | N/A |
| 12/31/2021 | 0 | -16 | -19 | -19 | N/A |
| 9/30/2021 | 0 | -19 | -21 | -21 | N/A |
| 6/30/2021 | 0 | -22 | -22 | -22 | N/A |
| 3/31/2021 | 0 | -25 | -23 | -23 | N/A |
| 12/31/2020 | 0 | -25 | -23 | -23 | N/A |
| 9/30/2020 | 0 | -24 | -23 | -23 | N/A |
| 6/30/2020 | 0 | -23 | -21 | -21 | N/A |
| 3/31/2020 | 2 | -19 | -21 | -21 | N/A |
| 12/31/2019 | 2 | -22 | -21 | -21 | N/A |
| 9/30/2019 | 2 | -21 | -21 | -21 | N/A |
| 6/30/2019 | 2 | -22 | -24 | -24 | N/A |
| 3/31/2019 | 1 | -23 | -24 | -24 | N/A |
| 12/31/2018 | 1 | -21 | -23 | -23 | N/A |
| 9/30/2018 | 1 | -21 | -22 | -22 | N/A |
| 6/30/2018 | 1 | -23 | N/A | -22 | N/A |
| 3/31/2018 | 1 | -21 | N/A | -23 | N/A |
| 12/31/2017 | 1 | -24 | N/A | -24 | N/A |
| 9/30/2017 | 1 | -23 | N/A | -24 | N/A |
| 6/30/2017 | 2 | -18 | N/A | -19 | N/A |
| 3/31/2017 | 4 | -21 | N/A | -17 | N/A |
| 12/31/2016 | 6 | -20 | N/A | -16 | N/A |
| 9/30/2016 | 15 | -11 | N/A | -16 | N/A |
| 6/30/2016 | 15 | -15 | N/A | -22 | N/A |
| 3/31/2016 | 13 | -19 | N/A | -26 | N/A |
| 12/31/2015 | 11 | -24 | N/A | -31 | N/A |
| 9/30/2015 | 2 | -41 | N/A | -40 | N/A |
| 6/30/2015 | 0 | -50 | N/A | -46 | N/A |
| 3/31/2015 | 0 | -57 | N/A | -51 | N/A |
| 12/31/2014 | 1 | -64 | N/A | -58 | N/A |
| 9/30/2014 | 3 | -65 | N/A | -61 | N/A |
| 6/30/2014 | 4 | -71 | N/A | -62 | N/A |
| 3/31/2014 | 4 | -68 | N/A | -64 | N/A |
| 12/31/2013 | 5 | -65 | N/A | -61 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 0T20's forecast earnings growth is above the savings rate (1%).
Earnings vs Market: Insufficient data to determine if 0T20's earnings are forecast to grow faster than the German market
High Growth Earnings: Insufficient data to determine if 0T20's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 0T20's revenue (1% per year) is forecast to grow slower than the German market (5.6% per year).
High Growth Revenue: 0T20's revenue (1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 0T20's Return on Equity is forecast to be high in 3 years time